Skip to main content

Advertisement

Table 1 Patient characteristics and clinical and molecular findings

From: Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis

Patient # Pathology Primary site/Recurrence DFI from surgery to relapse (mos) Number of lines before P Duration of P treatment (mos) Duration of P + S treatment (mos) Best RECIST response Best Choi response P dose (mg) S dose (mg) Procedures while on P + S Toxicity Status Genomic profile by FoundationOne
1 SFT Lung/Lung + heart 10 0 4 2 PD PD 400 4    AWD  
2 SFT Pleura/Duadenum + Spleen + liver 13 0 8 2 PD PD 600 4   Lethargy Dead NAB2-STAT6 fusion
               TP53 P278S
               AXIN1 A740T
               BRD4 truncation exon 8
3 UPS Limb/Lung 24 3 22 2 PD PD 800 3    Dead  
4 UPS Gluteus/Lung + pleura 41 3 6 5 PR PR 200 4   Glucose intolerance-metformin Dead  
5 ULMS Uterus/Lung 13 2 8 16 on going SD PR 400 3 Metastasectomy and SBRT Sub-febrile fever, glu intolerance-metformin AWD ALK IGFGP5-ALK fusion
               TSC2 splice site*
               CDKN2A loss
               TP53 L330P
6 LMS Limb/Lung 14 1 28 5 SD PR 400 3   Bowel perforation AWD  
7 DSRCT Retroperitoneum 0 3 12 11 SD PR 200 3   Proteinuria Dead  
8 UUS Uterus/Lung + retroperitoneum 3 1 4 1 PD PD 400 4    Dead  
9 Chondrosarcoma grade II Limb/Lung 47 1 0 3 on going SD PR 400 4    AWD CKS1B amplification
               MEF2C amplification
  1. *see Fig. 3